Pei-Hsinq Lai

Pei-Hsinq Lai

Auto-generated profile, based on publicly available information

Pei-Hsinq Lai

Department of Internal Medicine, Taipei City Hospital Zhongxiao Branch, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1991 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
NYN. Yasuda
N. Yasuda
PLP. K. Lai
P. K. Lai
JRJ. Rogers
J. Rogers
DPD. T. Purtlo
D. T. Purtlo
We studied the cellular function and lymphokine production of T cells from patients with X‐linked lymphoproliferative disease (XLP) when activated by the challenge with Epstein‐Barr virus (EBV) infection. We used an assay system in which T cells were stimulated with membrane antigens of autologous EBV‐infected B lymphoblastoid cell lines (B‐LCL) and we examined cellular and humoral factors derived from the stimulated T cells which control the growth of EBV‐inlected B‐LCL. Immunoglobulin secretion from the autologous B‐LCL was suppressed with radiosensitive suppressor cells in the patients with XLP. The degree of suppression was correlated with the immunoglobulin levels in the serum of the patients with acquired hypogammaglobulinaemia (P<0.05). In addition, T cells from the patients with XLP failed to produce interferon‐gamma (IFN‐γ) (P < 0.001). Moreover, the T cell supernatants from the patients with XLP were less potent to inhibit the B‐LCL growth. This diminished inhibition of the B‐LCL growth was correlated well with the decreased concentration of IFN‐γ in the T cell supernatants. These findings suggest that suppressor cells may be activated in the patients with the hypogammaglobulinaemia phenotype of XLP. but the frequent development of B cell lymphoma in hypogammaglobulinaemia indicate that immunoglobulin suppression may not exert enough pressure on the in vivo growth of EBV‐infected B cells. The defective secretion of IFN‐γ may be, at least partially, responsible for the abnormal cytotoxic T cell and natural killer activities found in the patients with XLP, and may indicate the clinical evaluation about the preventive injection of IFN‐γ against the development of malignant lymphoma.

6 August 2025 in Rheumatology
Verified
Journal Article
Closed access
TLTing-Yuan Lan
Ting-Yuan Lan
TLTai-Ju Lee
Tai-Ju Lee
TCTing-Wei Chang
Ting-Wei Chang
TTTai-Chung Tseng
Tai-Chung Tseng
PLPei-Hsinq Lai
Pei-Hsinq Lai
KLKo-Jen Li
Ko-Jen Li
Objective: HBV reactivation is a critical concern for patients with autoimmune disease undergoing immunosuppressive therapy. Despite data on HBV reactivation risks associated with biologics, the impact of the new targeted immunosuppressive agents—Janus kinase inhibitors (JAKis)—remains unclear. This study aimed to evaluate the risk of HBV reactivation among patients with RA treated with JAKis, compared with those receiving TNF inhibitors (TNFis) or rituximab. Method: We conducted a retrospective analysis of patients with RA treated at the National Taiwan University Hospital from 2015 to 2023. Patients with available baseline HBV status [HBsAg, hepatitis B core antibody (anti-HBc), hepatitis B surface antibody (anti-HBs), HBV DNA] who received TNFis, rituximab, or JAKis (tofacitinib, baricitinib, upadacitinib) were included. The primary outcomes were hepatitis flare in HBsAg-positive patients and HBsAg seroreversion in HBsAg-negative/anti-HBc–positive patients. Results: We included 35 HBsAg-positive patients and 339 patients with resolved HBV infection (HBsAg-negative/anti-HBc–positive). Among those with resolved HBV infection, the reactivation risk was low with TNFis (0.9%, 2.8/1000 person-years), and higher with rituximab (3.2%, 15.1/1000 person-years) and JAKis overall (2.9%, 10.3/1000 person-years). Among individual JAKis, upadacitinib had the highest incidence (6.5%, 42.8/1000 person-years), followed by baricitinib (4.7%, 19.2/1000 person-years), and tofacitinib (1.0%, 2.7/1000 person-years). Among HBsAg-positive patients, 50% of JAKi users developed a hepatitis flare, emphasizing the importance of vigilant monitoring and prophylaxis. Conclusion: Our findings reveal a non-negligible risk of HBV reactivation among RA patients receiving JAKi therapy, particularly with the more JAK1-selective JAKis. Larger registry or prospective studies are needed to validate these findings.

27 June 2025 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
PLPei-Hsinq Lai
Pei-Hsinq Lai
TLTing-Yuan Lan
Ting-Yuan Lan
CLCheng-hsun Lu
Cheng-hsun Lu
SHSong-Chou Hsieh
Song-Chou Hsieh
Since the COVID-19 pandemic, patients with immune-mediated inflammatory diseases (IMID) are recommended to receive SARS-CoV-2 vaccinations to reduce complications following COVID-19 infection. We conducted a case-control study and case analysis to investigate how SARS-CoV-2 vaccine platforms impact COVID-19 outcomes in patients with IMID on chronic rituximab therapies. Our findings suggest that exposure to protein-subunit vaccines were associated with the lowest mortality rates. Specifically, in the multivariate analysis of patients hospitalized for COVID-19, protein-subunit vaccines provided protection against all-cause mortality, particularly in those with lower pre-COVID-19 albumin levels, a surrogate for higher pre-COVID-19 inflammation. These results highlight the potential protective advantages of the protein-subunit vaccines, MVC-CoV1901 and NVX-CoV2373 vaccine, in patients with IMID. Moreover, our data supports heterologous vaccine regimens incorporating protein-subunit vaccines as a viable strategy for patients with IMID. Given the small sample size, further studies are needed to validate the clinical implications of this study.

31 July 2025 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
PLPei-Hsinq Lai
Pei-Hsinq Lai
CLCheng-hsun Lu
Cheng-hsun Lu
CCChiao-Feng Cheng
Chiao-Feng Cheng
TCTing-Wei Chang
Ting-Wei Chang
TLTing-Yuan Lan
Ting-Yuan Lan
SHSong-Chou Hsieh
Song-Chou Hsieh

25 July 2025 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
PLPei-Hsinq Lai
Pei-Hsinq Lai
SHSong-Chou Hsieh
Song-Chou Hsieh